antineoplastic agents such as paclitaxel, mitoxantrone and doxorubicin have been reported to induce AF. Whether bisphosphonate drugs are associated with new-onset AF remains controversial and requires further study. The potential contribution of specific drug therapy should be considered when patients present with new-onset AF.
Introduction
Atrial fibrillation (AF) is the most common arrhythmia encountered in clinical practice. [1] The prevalence of AF is 0.4-1%, and increases with age. [2, 3] AF is associated with symptoms, diminished quality of life, and leads to a doubling of the incidence of cardiovascular mortality and a 2-to 7-fold increase in the incidence of stroke. [1] Aetiologies and predisposing factors for AF are those that promote atrial and pulmonary vein dilatation and atrial fibrosis, and include hypertension, heart failure, valvular heart disease, coronary artery disease, inflammatory or infiltrative atrial disease, hyperthyroidism and a genetic predisposition (familial AF). [4] In addition, although drugs are more commonly recognized as causes of other arrhythmias such as torsades de pointes or sinus bradycardia, therapy with specific drugs has been associated with the development of AF.
Drug-induced AF was comprehensively reviewed by van der Hooft et al. [5] in 2004. Since that time, new information has become available regarding drug-induced AF, particularly in association with corticosteroids, as well as the controversial association of bisphosphonate drugs with AF. The purpose of this paper is to update and comprehensively review drug-induced AF, including specific drugs associated with this arrhythmia, incidences and potential mechanisms. Illicit drugs and caffeine are beyond the scope of this review and are therefore not discussed.
Ascribing causality to drug-associated AF is difficult, due to the nature of reports of druginduced AF, as well as due to the fact that, unlike drug-induced torsades de pointes, for which there is a biomarker of risk (QT interval), there is no clear biomarker for drug-induced AF. For some drugs, there are multiple studies assessing a potential association between a specific drug and newonset AF, but many of the studies show conflicting results. Throughout this manuscript, we have used a literature-derived 'Quality of Evidence' designation to indicate the quality of evidence associating specific drugs with the occurrence of AF (table I) . [6] 
Potential Mechanisms of Drug-Induced Atrial Fibrillation
The initiation of AF requires a trigger impulse, while the maintenance of AF requires an electrophysiological substrate. [4] There is evidence that triggering ectopic impulses can occur in pulmonary and other thoracic veins, near the atrial junction, or directly in the atrial muscle. Once an ectopic Table I . Quality of evidence associating drugs with new-onset atrial fibrillation (reproduced from American Geriatrics Society, [6] with permission)
Quality of evidence Description

High
Evidence includes consistent results from well designed, well conducted studies in representative populations (two or more consistent, higher quality randomized controlled trials or multiple, consistent, observational studies with no major methodological flaws)
Moderate
Evidence is sufficient to determine effects on occurrence of AF, but the number, quality, size or consistency of included studies, generalizability to routine practice, or indirect nature of the evidence on induction of AF (one or more higher quality trial with >100 participants; two or more consistent, lower quality trials or multiple, consistent observational studies with no major methodological flaws) limits the strength of the evidence Low Evidence is insufficient to assess the association of drugs with AF because the evidence is from case reports only, or because of limited number or power of studies, large and unexplained inconsistency between higher quality studies, important flaws in study design or conduct, gaps in the chain of evidence, or lack of information on important healthcare outcomes
impulse is propagated to the atrium, a substrate is necessary to perpetuate the impulse through reentrant circuits. The susceptibility of the atria to reentry is related to cardiac wavelength, defined as the product of the atrial conduction velocity and the atrial effective refractory period (ERP). However, it has been suggested that rapid focal activity alone can prompt the generation of AF. [7, 8] Theoretically, drug-induced AF can occur through either pharmacological stimulation that promotes ectopic impulses or by modulating the underlying substrate by shortening of cardiac wavelengths. Some important risk factors for the generation of AF include advanced age, alcohol consumption, cardiac surgery and a family history of AF. Additionally, co-morbid conditions such as chronic obstructive pulmonary disease, hypertension, hyperthyroidism, sleep apnoea, previous myocardial infarction and heart failure commonly co-exist with the development of AF. Many of these risk factors influence underlying physiological and pathophysiological conditions that promote a substrate for AF. These risk factors occur frequently in patients in whom drug-induced AF is suspected and it is important to consider these when evaluating the potential for drug-induced AF.
Common underlying conditions that may induce AF include activation of the autonomic nervous system, local or systemic inflammation, atrial fibrosis and atrial stretch. For example, paroxysmal AF is frequently preceded by brief changes in autonomic tone. [9] Both parasympathetic and sympathetic activation alter intracellular calcium dynamics and can shorten action potential duration and refractoriness. [10, 11] During sympathovagal stimulation there is decreased atrial repolarization in the presence of increased calcium transients, which may promote early afterdepolarizations and triggered activity. [10, 11] The result is an ectopic firing that has been proposed to be primarily localized to the sleeves of atrial muscles that surround the pulmonary veins. [10, 11] In addition to these neurohormonal influences, structural and mechanical changes in the atria may be proarrhythmic. In experimental models, the mechanoelectrical feedback associated with atrial stretching has been associated with alterations in atrial refractoriness. Additionally, atrial fibrosis can alter atrial conduction in a manner that can be proarrhythmic by facilitating reentry.
In summary, AF can result from a number of mechanisms that may be influenced by an underlying pathophysiological state and concurrent risk factors. Many of the drugs that have been linked to increasing the risk for AF modify these risk factors or underlying pathophysiological conditions.
Literature Search Methods
The PubMed, MEDLINE and Micromedex databases were selected to evaluate reports on drug-induced AF published in English between January 1978 and April 2011. Key words 'atrial fibrillation' and 'arrhythmia' combined with 'druginduced', 'chemically-induced', 'adverse effect', 'adverse event', 'associated with drug', 'as cause of drug' and 'as side effect' were used. In some cases, reference citations from selected review articles were also used. Additional screening was done by searching individual drug names. Medications for which AF is listed as a potential adverse effect, but without identified case reports, were excluded. Drugs associated with AF are listed in table II. Although adenosine is effective at terminating supraventricular tachycardias with atrioventricular (AV) nodal involvement, it may induce AF, with an incidence of 1-12%. [12] [13] [14] Episodes of adenosine-induced AF have been reported to be short lived and transient during stress testing, as a result of adenosine's short half-life (10 seconds). A case series of eight patients with adenosineinduced AF reported that the arrhythmia duration ranged between 15 seconds and 8 hours and converted to sinus rhythm without intervention or complication. [15] However, there can be significant clinical consequences in a subset of patients with an accessory pathway, such as those with Wolff-Parkinson-White syndrome. Case studies have reported haemodynamic instability due to a rapid ventricular response from adenosine-induced AF in patients with accessory pathways. [16, 17] Adenosine is largely effective at terminating supraventricular tachycardias due to its slowing of AV nodal conduction. However, in atrial tissue, adenosine enhances activity of the acetylcholine-activated inward rectifier potassium current (I K(ACh) ). [18] The resulting shortening of atrial repolarization and ERPs may promote reentry. [13, 19] In addition to its direct electrophysiological effects, adenosine may enhance adrenergic tone, which may increase the risk of AF. [20] In summary, adenosine may enhance the substrate for AF by direct electrophysiological effects or by enhancing autonomic tone. Although adenosine-induced AF is often clinically inconsequential, it can be of significant clinical importance when an accessory pathway is present. Although adenosine-induced AF is usually of short duration, patients undergoing therapy with adenosine should undergo continuous telemetry electrocardiogram (ECG) monitoring to identify AF should it occur.
Cardiovascular Drugs
Dobutamine (Quality of Evidence -High)
Dobutamine is an inotropic agent that acts directly through b-adrenergic receptor activation to increase automaticity and conduction velocity while shortening ERPs. [21] b-adrenergic receptor activation increases the risk of AF through enhancement of intracellular 3 0 -5 0 -cyclic adenosine monophosphate (cAMP). Increased cAMP activates protein kinase A, which enhances the activity of several target proteins such as the ryanodine receptor, phospholamban and the L-type calcium channel, modulating intracellular calcium cycling. The resulting cytosolic calcium accumulation can trigger depolarizations in pulmonary veins and atrial tissue to trigger AF, which can be perpetuated by reentry or rapid atrial depolarizations. Increased calcium loading triggers ectopic impulses and is one mechanism of adrenergically mediated AF. [4, 22] Ventricular dysfunction after cardiac surgery can necessitate the administration of vasopressors and/or inotropic agents to maintain haemodynamic stability. Given the mechanism of neurally induced AF, it is not surprising that the use of an agent with a predominant adrenergic component is an independent predictor of postoperative AF. [23] In a sample of 127 patients undergoing cardiac surgery and treated with an inotropic agent, 49 (39%) developed postoperative AF (p < 0.01 compared with [5] with further evidence documented after 2004. 
of 72 [14%] in the control group)
. Dopamine and dobutamine were used in 44% and 41% of the patients who developed postoperative AF, respectively. [23] The outcomes of drug-induced AF in this population have not been assessed, but the development of AF following cardiac surgery prolongs duration of hospital stay and increases morbidity. [24, 25] The incidence of dobutamine-induced AF in non-surgical patients with acute decompensated heart failure is unclear due to the lack of an appropriate comparator group. The best data available regarding dobutamine-induced AF in patients with acute decompensated heart failure were from clinical trials of levosimendan in which dobutamine was used as the comparator drug. Levosimendan is a positive inotropic agent that is used for the management of acute decompensated heart failure in Europe but has not been approved for use in the US. It is mechanistically distinct from dobutamine and the phosphodiesterase inhibitors (e.g. milrinone) because it does not exert its inotropic effects through b-adrenergic receptors, nor does it increase intracellular cAMP. Levosimendan exerts its inotropic effects by directly binding to cardiac troponin C. It also possesses vasodilatory actions through modulation of the adenosine triphosphate (ATP)-dependent potassium channel. Therefore, it was initially believed that levosimendan would not have arrhythmogenic effects since it does not enhance intracellular calcium dynamics through protein kinase A (PKA) activity. Patients with acute decompensated heart failure were randomized to levosimendan versus dobutamine in the SURVIVE (Survival of Patients With Acute Heart Failure in Need of Intravenous Inotropic Support) trial. [26] Patients administered levosimendan had a significantly greater incidence of AF than those who received dobutamine: 60/660 (9.1%) versus 40/660 (6.1%), respectively. [26] Since the SURVIVE trial, other evidence has been reported indicating that levosimendan may not incur a greater risk of AF over dobutamine in patients on optimal therapy for New York Heart Association class III or IV heart failure including a b-blocker. [27] There is strong mechanistic theory to suggest that dobutamine would increase the risk for AF in patients with acute decompensated heart failure. However, it is difficult to draw any solid conclusions regarding the incidence of dobutamine-induced AF in this high-risk population. Furthermore, the benefit of administering inotropic agents in these patients outweighs the risk of developing AF. Therefore, the risk of dobutamine-induced AF should not preclude its use in patients with decompensated heart failure.
Dobutamine stress echocardiography has been reported to induce AF in 1-4% of patients, with serious AF requiring treatment occurring in fewer than 0.18% of patients. [28] [29] [30] [31] Dobutamine-induced AF during stress echocardiography is usually transient and spontaneously reverts to sinus rhythm within hours. Nonetheless, it can compromise the diagnostic value of the stress test and in some cases lead to hospitalization. Therefore, studies have been conducted to help identify patients at the highest risk for dobutamine-induced AF. [29, 32] Risk factors include hypertension and echocardiographic findings, including left ventricular hypertrophy, increased left atrial diameter and mitral regurgitation. The best predictor of dobutamineinduced AF is a history of AF. In summary, dobutamine-induced AF is relatively uncommon following stress echocardiography and to some extent can be predicted by a previous history of AF or current risk factors. Alternatives should be considered in patients at high risk or with previous AF undergoing stress echocardiography with dobutamine. However, given the transient nature of AF in most cases, the benefits of using dobutamine outweigh the risks in most cases. Patients receiving therapy with dobutamine should undergo continuous telemetry ECG monitoring.
Milrinone (Quality of Evidence -Moderate)
Milrinone is a phosphodiesterase inhibitor that increases intracellular cAMP while bypassing the b-adrenergic receptor pathway to exert a positive inotropic effect and vasodilation. Similar to dobutamine, milrinone administration likely results in cytosolic calcium accumulation, which can trigger ectopic impulses in pulmonary veins or atrial tissue to promote AF. Therefore, it is not surprising that milrinone increased the risk of atrial arrhythmias when used for short-term management of heart failure exacerbations that did not require the use of inotropic agents (4.6% vs 1.5%; p < 0.01) in a randomized, placebocontrolled clinical trial. [33] These numbers of AF induction are important to note in this population given the rare use of a placebo in the comparator group to assess the ability of a drug to induce AF. This is particularly important given the high incidence of AF during heart failure, which is likely due to increased sympathetic tone and intracellular calcium accumulation.
The haemodynamic effects of dobutamine and milrinone, and subsequently the risk for the development of AF following cardiac surgery, were compared. [34] During the 4-hour infusion, 5% (n = 3) of the 60 patients who were administered milrinone developed AF versus 18% (n = 11) of the 60 patients who were administered dobutamine (p = 0.04). [34] More recently, an interim analysis of an ongoing clinical trial identified milrinone as an independent risk factor for postoperative AF in patients undergoing elective cardiac surgery. Of the patients assessed, 29% (67/232) developed postoperative AF. Milrinone administration was associated with a higher incidence of AF (58.2%) versus non-users (26.1%; p < 0.001). [35] Postoperative AF increases the length of hospital stay and may be associated with increased mortality. [24, 25] In summary, the use of milrinone for heart failure increases the risk of AF. Similar to dobutamine, the clinical use of milrinone should not be deterred during acute decompensated heart failure due to concerns about AF. Due to the lack alternative inotropic agents that do not promote AF, the clinician should closely monitor and appropriately treat AF if it occurs during the course of therapy. Additionally, the use of milrinone to preserve haemodynamic stability following cardiac surgery likely increases the risk for AF in a similar manner to that of dopamine and dobutamine. Alternatives to the use of inotropic agents to preserve haemodynamic stability following surgery should be considered given the wealth of data suggesting that post-operative AF increases morbidity and perhaps mortality. Patients receiving therapy with milrinone should undergo continuous telemetry ECG monitoring. Several antiarrhythmic agents used for the conversion of AF can promote the transition to an atrial flutter-like arrhythmia. The mechanism for the conversion from AF to atrial flutter is likely stabilization of reentry by prolongation of cardiac wavelength until one macro-reentrant circuit predominates. This phenomena has been reported for the Vaughan Williams class IC agents propafenone and flecainide, with a reported incidence of up to 20%. [36, 37] The treatment of antiarrhythmic druginduced atrial flutter with radiofrequency ablation may permit the continued administration of the antiarrhythmic agent. A detailed description of drug-induced atrial flutter is beyond the scope of this review.
Amiodarone (Quality of Evidence -Low)
Amiodarone is an effective agent to convert AF and maintain sinus rhythm. Similar to other antiarrhythmic drugs, amiodarone administration can prompt arrhythmias similar to atrial flutter when administered to patients with AF. [38, 39] Additionally, in rare occurrences, amiodarone may indirectly promote AF through its non-cardiac adverse effects.
Amiodarone-induced thyrotoxicosis (AIT) has been reported in two case studies to indirectly promote AF. [40, 41] Both patients were receiving chronic oral amiodarone for approximately 1.5 and 2.5 years duration. Both patients presented to the emergency department with palpitations and weakness that was identified as AF 5 and 6 months, respectively, after discontinuation of amiodarone treatment. In both cases, AF was attributed to a newly diagnosed late-onset AIT. The delayed onset of AIT and subsequent amiodarone-induced AF may lead to an underestimation of the drug's ability to promote this arrhythmia. That is, if thyrotoxicosis occurs several months after amiodarone discontinuation, the potential for the drug to provoke AF may be overlooked. Nonetheless, once AF presents and is determined to be due to AIT, the precipitating factor of thyroid dysfunction should be treated. Amiodarone-induced AF is uncommon, and the potential for AF should not be a factor in prescribing decisions for most patients.
Calcium Channel Blockers (Quality of Evidence -Low)
Calcium channel blockers (CCBs), both dihydropyridines and nondihydropyridines, have been reported to potentially increase the risk of AF despite widespread use of nondihydropyridine CCBs for the management of AF. It has recently been reported that in 682 993 hypertensive patients, those treated with angiotensin-converting enzyme (ACE) inhibitors, angiotensin II receptor blockers or b-blockers had a reduced risk of AF compared with those receiving CCBs. [42] This could be due to beneficial effects of the former drugs or due to an increased risk from CCBs. Theoretically, CCBs could increase the risk for AF by a several mechanisms. First of all, the compensatory effect of decreased blood pressure may result in an increased sympathetic drive to promote neural-induced AF. Secondly, it has been demonstrated in dogs that verapamil promotes multiple circuit reentry by shortening atrial ERPs and increases simultaneous wavefronts. [43] This resulted in an incidence of AF that was not observed in control or diltiazem-treated dogs. [43] Finally, CCB-induced AF was associated with left atrial overload in patients with hypertrophic cardiomyopathy. [44] This was suggested to be due to an increased left ventricular outflow gradient that was previously reported with sublingual nitroglycerin and other vasodilatory agents. [45] 4. Bisphosphonates (Quality of Evidence -Low)
A large number of studies have been conducted regarding the possible association between bisphosphonate drugs and development of new-onset AF. However, much of the evidence is conflicting and equivocal. A summary of the evidence supporting or refuting an association between bisphosphonates and the development of AF is provided in table III. [46] [47] [48] [49] [50] [51] [52] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] The first evidence that bisphosphonates may be associated with AF was provided by the HORIZON (Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly) Pivotal Fracture Trial, which was a multicentre, randomized, double-blind, placebocontrolled study in 7765 postmenopausal women with osteoporosis. [46] While once-yearly intravenous zoledronic acid 5 mg was effective for reducing the incidence of vertebral, hip and other fractures during the 3-year follow-up period, the incidence of 'serious' AF was significantly higher in the zoledronic acid group (1.3%) than in the placebo group (0.5%; p < 0.001). [46] A definition of 'serious' AF was not provided in this study. There was no significant difference between the zoledronic acid and placebo groups in the overall incidence of AF. In FIT (Fracture Intervention Trial), 6459 postmenopausal women with osteoporosis were randomized to receive oral alendronate 5 mg once daily or placebo. [67] There was a trend towards an increased incidence of serious AF (definition of 'serious' was not provided) in patients treated with alendronate (1.5%) compared with placebo (1.0%; p = 0.07); there was no significant difference between alendronate and placebo groups in the overall incidence of AF (2.5% vs 2.2%; p = 0.42). [47] In contrast to the findings of the HORIZON Pivotal Fracture Trial, [46] the HORIZON Recurrent Fracture Trial [54] reported no significant difference between the zoledronic acid and placebo groups in the incidence of serious AF. Similarly, in a retrospective analysis of placebo-controlled phase III trials (approximately 15 000 patients, mean age 74 years, up to 3 years follow-up) in patients with osteoporosis, there was no significant difference in the incidence of AF or serious AF associated with risedronate compared with placebo. [55] In view of findings of increased risk of serious AF in studies described above, numerous investigators subsequently conducted cohort or casecontrol studies to determine possible associations between bisphosphonate therapy and AF. Findings from some cohort studies supported a significant association between bisphosphonate use and development of AF [48, 49] while others did not. [56] [57] [58] One retrospective cohort study even reported that bisphosphonates may reduce, rather than increase, the risk of AF in older women with osteoporosis. [68] One case-control study reported an association between bisphosphonate use and AF, [50] while others did not. [59, 60] As a result of these disparate findings, several meta-analyses have been performed to determine if the weight of published evidence supports that bisphosphonate therapy induces AF. [51, 52, [61] [62] [63] [64] These meta-analyses have also reported disparate findings (table III) .
Overall, data regarding the association between bisphosphonate therapy and AF are equi- Studies reporting an association between bisphosphonate drugs and development of AF Zoledronic acid [46] r, db, pc 0.8 b *
Alendronate [47] r, db, pc 0.5 b HR 1.51 (0.97, 2.40)
Oral bisphosphonates [48] Cohort HR 1.18 (1.08, 1.29)
IV bisphosphonates [49] Cohort HR 1.30 (1.18, 1.43)
Alendronate [50] Case control OR 1.86 (1.09, 3.15)
Bisphosphonates [51] Meta-analysis OR 1.47 (1.01, 2.14)
b
Bisphosphonates [52] Meta-analysis RR 1.53 (1.17, 2.00)
Bisphosphonates [53] Cohort HR 1.7 (1.2, 2.4)
Studies reporting no association between bisphosphonate drugs and development of AF Zoledronic acid [46] r, db, pc 0.5
Alendronate [47] r, db, pc 0.3 HR 1.14 (0.83, 1.57)
Zoledronic acid [54] r, db, pc 0.2 Risedronate [55] r, db, pc 0. Bisphosphonates [51] Meta-analysis OR 1.14 (0.96, 1.36)
Bisphosphonates [61] Meta-analysis OR 1.18 (0.84, 1.66) RR 1.60 (0.61, 3.75)
Ibandronate [62] Meta-analysis HR 1.15 (0.52, 2.54)
Bisphosphonates [63] Meta-analysis OR 1.04 (0.92, 1.16) Alendronate [64] Meta-analysis RR Zoledronic acid [66] Retrospective, uncontrolled 0 a Incidence in placebo group subtracted from incidence in bisphosphonate group.
b Serious AF.
c New users.
d Continuing users.
e Three databases studied; relative risks provided for each database. AF = atrial fibrillation; db = double-blind; HR = hazard ratio; IV = intravenous; OR = odds ratio; pc = placebo controlled; r = randomized; RR = relative risk; * p < 0.001 vs placebo.
vocal, and it remains unclear whether bisphosphonate drugs contribute to the development of new AF. Reasons for the disparate findings from clinical trials and the various cohort studies and case-control studies are not entirely clear, although these studies differ in study design, patient inclusion and data analysis, among other variations. Based on available data, bisphosphonate drugs should not be withheld from patients with osteoporosis or cancer based on concerns for the potential for AF. However, when treating patients with pre-existing risk factors for signs and symptoms of AF with bisphosphonate drugs, it seems prudent to monitor for symptoms of newonset AF. Routine ECGs are not warranted at this time.
Corticosteroids (Quality of Evidence -Low)
Several published reports have associated corticosteroids, primarily methylprednisolone, with development of AF. AF has been attributed to the administration of high-dose methylprednisolone in pulse doses, [69] [70] [71] [72] but also with lower dose intravenous or oral methylprednisolone therapy. [73] [74] [75] In a nested case-control study of individuals 55 years of age or older in Rotterdam, the Netherlands, [76] the adjusted odds ratio (OR) for newonset AF associated with corticosteroid therapy was 3.75 (95% CI 2.38, 5.87). The association was significant only among patients who received high doses (OR 6.07, 95% CI 3.90, 9.42), defined as ‡7.5 mg prednisone equivalents daily. In another nested case-control study of primary care patients between the ages of 40 and 89 years enrolled in the UK General Practice Research Database, current corticosteroid use was associated with an increased risk of chronic AF (relative risk [RR] 2.49, 95% CI 1.56, 3.97). [77] However, there was no significant association between corticosteroid use and development of paroxysmal AF.
In contrast, studies have found that corticosteroids are effective for prophylaxis of AF following coronary artery bypass graft (CABG) surgery. [78] [79] [80] [81] Reasons that corticosteroids may be effective for prevention of post-CABG AF but associated with induction of AF in patients not undergoing surgery are unclear. Evidence indicates that AF may occur in part as a result of an inflammatory process; inflammation may be particularly important as a mechanism of postoperative AF, and corticosteroids may reduce the risk of post-CABG AF due to anti-inflammatory properties. [82] On the other hand, mechanisms by which corticosteroids may contribute to causing nonsurgical AF have been suggested, [76] and include sodium and fluid retention, leading to elevated atrial pressures; modulation of myocardial potassium efflux; [83] and promotion of the development of late potentials. [84] Additional research is needed to clarify the effects of corticosteroids on inducing AF and/or preventing post-CABG AF.
Central Nervous System Agents
Ondansetron (Quality of Evidence -Low)
Ondansetron is a 5-hydroxytryptamine 3 (5-HT 3 ) receptor antagonist used for prophylaxis and treatment of postoperative nausea and vomiting. Although ondansetron has been linked to acute myocardial ischaemia and tachyarrhythmias, AF has not been widely reported. Two case reports discuss the onset of AF shortly after the administration of a second intravenous dose of ondansetron 4 mg. The patients had unremarkable past medical histories and no evidence of cardiac disease upon further testing. Both cases reported the need for antiarrhythmics or direct current cardioversion to restore sinus rhythm. Sympathovagal stimulation during vomiting may play a role in AF development. Coronary vasoconstriction and the inhibition of the Bezold-Jarisch cardiac reflex have been suggested to play a role in ondansetron-associated AF. [85, 86] 7. Antineoplastic Agents Antineoplastic agents are frequently used in combination with other antineoplastic drugs, immunological agents and steroids. Therefore, use of one or more agents that have a propensity to induce AF can theoretically put a patient at an increased risk of developing this arrhythmia. More research is needed to evaluate the potentially ad-ditive proarrhythmic toxicities of multiple-agent chemotherapy regimens. Paclitaxel, an antimicrotubule agent, induces atrial flutter and AF infrequently (up to 2% and 1-1.7%, respectively). [87, 88] A retrospective study evaluated the cardiac toxicity associated with paclitaxel in 100 African-American patients with various cancers. [87] Doses ranged from 75 to 200 mg/m 2 and were administered every 1-3 weeks. Sinus tachycardia occurred in 26% of treated patients; AF occurred in 1%. The onset of cardiac disturbances ranged from day 1 to 8 years after paclitaxel administration. These changes were described as mild, reversible and likely dose independent. Moreover, the authors indicated that 60% of the study population had underlying co-morbid conditions, and up to 80% had cardiac risk factors. The presence of paclitaxel may have potentiated AF development in this group of patients with many comorbid conditions. A single case of tachycardia and AF was reported in a phase II study during which 58 breast cancer patients received long-term weekly infusions of paclitaxel. [88] Paclitaxel was administered weekly at doses ranging between 60 and 90 mg/m 2 , with patients receiving a median of 19 weekly infusions, corresponding to a median cumulative dose of 1280 mg/m 2 . The authors suggested that some adverse effects, especially neurotoxicity and onychopathy, may be related to the cumulative dose of paclitaxel; but the relationship between cumulative dose and occurrence of AF is unknown. In an analysis of approximately 3400 patients in the National Cancer Institute's adverse drug reaction database, atrial arrhythmias occurred in fewer than 0.2% of patients who received paclitaxel. [89] 7.2 Interleukin-2 (Quality of Evidence -Moderate)
In a phase II trial of outpatient subcutaneous interleukin (IL)-2 combined with interferon-a in 47 patients with metastatic renal cell cancer, two patients (4.3%) developed AF requiring treatment. [90] One of these patients developed treatmentrelated hyperthyroidism, which may have been the aetiology of the AF. Similarly, AF developed in 4 of 93 (4.3%) patients with metastatic melanoma, metastatic renal cell cancer and colorectal cancer in another analysis involving high-dose intravenous IL-2 plus lymphokine-activated killer cells. [91] In an analysis of 317 patients with various cancers treated with 423 courses of IL-2, 8% of the treatment courses resulted in AF. [92] Mechanisms of AF associated with IL-2 are unclear, although there is some evidence to suggest that elevation of plasma cytokine concentrations in general may be associated with AF. [93] 7.3 Anthracyclines [Doxorubicin and Mitoxantrone] (Quality of Evidence -Low)
Anthracyclines are well known for cardiotoxic effects, ranging from tachycardia to cardiomyopathy. Dilated cardiomyopathy is a dose-limiting factor for doxorubicin use. [94] A prospective study by Kilickap et al. [94] investigated the arrhythmogenic effects of doxorubicin-containing regimens in 29 patients with various cancers in the acute/ early (during and 23 hours after first infusion) and chronic/late (at least 6 weeks after last cycle) stages of treatment. The median cumulative doxorubicin dosage was 50-480 mg/m 2 . Abnormal cardiac rhythms were reported in 19 patients (65.5%) and 18 patients (64.2%) in the acute and chronic phases, respectively. Paroxysmal AF was recorded in three patients (10.3%) in the acute phase, but was not reported in the chronic phase. Concurrent use of antiemetic medications as well as various chemotherapy regimens (5-fluorouracil and cyclophosphamide) may have potentially contributed to a higher incidence of arrhythmias, including AF, in the acute phase. This study showed that rhythm disturbances can occur in both the acute and the chronic phases after doxorubicin therapy. In the acute phase, it has been hypothesized that vasoactive substances, enhanced sympathetic activity, and hypotension during and after doxorubicin infusion may play a role in the development of ECG changes and rhythm disturbances. Dilated cardiomyopathy leading to arrhythmias in the chronic stage is also a concern. This typically occurs several years after completion of therapy and the incidence is usually limited to less than 5% if the cumulative dose is less than 550 mg/m 2 .
[ 94] Mitoxantrone has been associated with decreased left ventricular ejection fraction, irreversible cardiomyopathy and heart failure. In a prospective study of 73 multiple sclerosis patients, AF developed in one patient with a history of ischaemic heart disease and hypertension after the second course of mitoxantrone. The patient was later excluded from the study, and no information regarding the duration of AF was provided. [95] There is some evidence to suggest that the cardiac side effects of mitoxantrone may be related to higher cumulative doses. [95] Heart failure development can also lead to AF. In this specific case, it is plausible that AF may have been potentiated since mitoxantrone was administered in combination with methylprednisolone, another medication that has also been linked with development of AF. [76] 
Conclusions
Several drug classes have been associated with AF. The strongest evidence of an association with new-onset AF exists for adenosine, dobutamine, aminophylline/theophylline and alcohol binging, with moderate-quality evidence available for milrinone, IL-2, cisplatin, melphalan, amifostine, and flecainide and propafenone (for atrial flutter). Bisphosphonate drugs and corticosteroids, predominantly high-dose methylprednisolone, have been reported in clinical trials to be associated with AF, but evidence is conflicting and equivocal. Therefore, the question as to whether bisphosphonate drugs and corticosteroids are associated with new-onset AF remains controversial and requires further study. An association between AF and drugs such as dopamine, amiodarone, CCBs, ondansetron, paclitaxel and anthracyclines is supported by relatively weak evidence, but cannot be ruled out. The potential contribution of specific drug therapy should be considered when patients present with new-onset AF.
